Deals: Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelhei ...
Fintel reports that on October 17, 2025, Guggenheim maintained coverage of Praxis Precision Medicines (NasdaqGS:PRAX) with a ...
Fintel reports that on October 17, 2025, Truist Securities reiterated coverage of Praxis Precision Medicines (NasdaqGS:PRAX) ...
Bolstered by a late-stage trial win for its essential tremor drug, Praxis Precision Medicines Inc. is looking to raise $525 ...
Praxis Precision Medicines PRAX stock surged after Phase 3 trials for its essential tremor drug met endpoints, prompting TD ...
We recently published Market Downturn? Not for these 10 Stocks; 7 Jump to Record Highs. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best performers on Thursday. Praxis Precision ...
The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program aimed at addressing unmet public health needs by shortening regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback